Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo …
K Strojek, KH Yoon, V Hruba, M Elze… - Diabetes, Obesity …, 2011 - Wiley Online Library
Aims: Progressive deterioration of glycaemic control in type 2 diabetes mellitus (T2DM) often
requires treatment intensification. Dapagliflozin increases urinary glucose excretion by …
requires treatment intensification. Dapagliflozin increases urinary glucose excretion by …
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
RA DeFronzo, M Hompesch, S Kasichayanula… - Diabetes …, 2013 - Am Diabetes Assoc
OBJECTIVE To examine the effect of dapagliflozin, a sodium-glucose cotransporter 2
(SGLT2) inhibitor, on the major components of renal glucose reabsorption (decreased …
(SGLT2) inhibitor, on the major components of renal glucose reabsorption (decreased …
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active …
HJL Heerspink, A Kiyosue, DC Wheeler, M Lin… - The Lancet, 2023 - thelancet.com
Background In patients with chronic kidney disease, SGLT2 inhibitors and endothelin A
receptor antagonists (ERAs) can reduce albuminuria and glomerular filtration rate (GFR) …
receptor antagonists (ERAs) can reduce albuminuria and glomerular filtration rate (GFR) …
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
JF List, V Woo, E Morales, W Tang… - Diabetes care, 2009 - Am Diabetes Assoc
OBJECTIVE Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows
an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple …
an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple …
Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial
OBJECTIVE In patients with moderate to severe albuminuric kidney disease, sodium–
glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post …
glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post …
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
N Staplin, R Haynes, PK Judge, C Wanner… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of
chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range …
chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range …
Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule
Kidneys contribute to glucose homeostasis by reabsorbing filtered glucose in the proximal
tubules via sodium-glucose cotransporters (SGLTs). Reabsorption is primarily handled by …
tubules via sodium-glucose cotransporters (SGLTs). Reabsorption is primarily handled by …
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in …
S Kasichayanula, X Liu, WC Shyu… - Diabetes, Obesity …, 2011 - Wiley Online Library
Aims: Dapagliflozin increases urinary glucose excretion by selectively inhibiting renal
sodium–glucose transporter 2, an insulin‐independent mechanism of action that may be …
sodium–glucose transporter 2, an insulin‐independent mechanism of action that may be …
Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial
JC Laursen, N Søndergaard-Heinrich… - …, 2021 - thelancet.com
Background Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression
of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with …
of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with …
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors may have renal protective
effects in people with impaired kidney function. We assessed the use of SGLT2 inhibitors in …
effects in people with impaired kidney function. We assessed the use of SGLT2 inhibitors in …